Center-Authored Papers

Filters: Author is Maris, John M  [Clear All Filters]
C
Chmielecki J, Bailey M, He J, Elvin J, Vergilio J-A, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S et al..  2017.  Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.. Cancer research. 77(2):509-519. Abstract
E
Erbe AK, Wang W, Reville PK, Carmichael L, Kim KM, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A et al..  2017.  HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.. FRONTIERS IN IMMUNOLOGY. 8 Abstract
K
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L et al..  2013.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.. The lancet oncology. 14(10):999-1008. Abstract
M
Maris JM, Healy J, Park J, Ladenstein R, Pötschger U.  2015.  G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Letter.. Cancer research.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes S-E-N, Diccianni MB, Sondel PM et al..  2017.  Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.. The Lancet. Oncology. Abstract
P
Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG et al..  2017.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016720177. Abstract
W
Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look TA et al..  2013.  Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group.. Cancer. Abstract